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Abstract The significance of the role of nitric oxide (NO)
in cancer is evident from 1,100 publications on the subject;
its triggering of apoptosis at high concentrations is
documented in 300 publications. While aspects of the rate
of generation of NO in tumors have been extensively
studied, the rate of its removal from tumors has not been
considered, even though it is the difference between the two
rates that determines the all important steady-state NO
concentration, and thus the likelihood of apoptosis-
triggering. The rate of transport of NO scales with its
concentration gradient at the interface between a neoplasm
and the phase to which it diffuses, which can be air, fat, or
blood. Diffusional loss of NO to air would explain the
initial two-dimensionality of neoplasms of the skin and
lung. The greater solubility of NO in lipids than in aqueous
phases should cause its extraction by nearby fat, and would
account for the positive correlation between obesity and the
incidence of some cancers, such as cancers of the breast.
And the rapid consumption of NO by red blood cells
implies depletion of excess NO in tumors after they are
vascularized: angiogenesis should blunt any apoptosis-
triggering NO attack of the immune system. Thus, cancer
research and the practice of oncology may benefit of in-
tumor monitoring of the actual NO concentration. Minia-
ture NO monitoring electrodes, that might serve the
purpose, are reviewed.
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Introduction
One thousand and one hundred articles have been published
on the role of nitric oxide (NO) in cancer. The immune
system recognizes neoplasms and attacks, or attempts to
attack, these by increasing the NO concentration. NO is the
smallest, fastest-diffusing, water- and lipid-soluble,
membrane-permeating molecule in the immune system’s
arsenal. To raise the local NO concentration in the
neoplasm, the immune system increases the local iNOS
activity, for example by local recruiting and stimulation of
macrophages. Three hundred publications, 40 on cancer,
show that at high concentrations NO triggers apoptosis. The
apoptosis-triggering NO concentrations are >1 μM, about a
thousand-fold higher than the vasodilation-causing concen-
trations. Nevertheless, the actual tumor NO concentrations
are rarely monitored. While most of the 1,100 publications
consider an aspect of the generation of NO, few, if any,
consider the equally important removal of nitric oxide from
tumors. The most often-measured NO-generation-related
parameters are the expression of inducible nitric oxide
synthase, iNOS, and the expression of endothelial nitric
oxide synthase, eNOS. Both enzymes catalyze Reaction 1.
Other frequently measured NO-generation related parameters
Arginineþ O2 ! citrullineþ NO ð1Þ
are the expression of iNOS at the mRNA level; the expressions
of cytokines inducing or inhibiting iNOS expression; the actual
iNOS activity in the tumor; concentrations of NO2
− and NO3
−,
both products of NO; NO2
−-concentration dependent diazoti-
zations, whereby colored or fluorescent products are formed;
and, in a few publications, the concentration of arginine, the
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precursor of NO (Reaction 1). In some neoplasms the
generation of excess NO is impaired [1].
The all important steady-state NO concentration in tumors
depends equally on both the rate of NO generation and on the
rate of NO elimination. The latter has not been sufficiently
considered. In absence of actual tumor NO concentration
measurements, and in absence of estimates of NO elimination
rates in neoplasms, there is no information on the steady-state
NO concentration, even though it may determine the relative
rates of cell proliferation and apoptosis.
NO dissolves and diffuses in both lipids and aqueous
solutions. It permeates through cell membranes [2], walls of
blood-vessels, and skin. Consequently, it is eliminated by
1. out-diffusion from air-contacting neoplasms to ambient air;
2. extraction by, and oxidation in, proximal fat (Reaction 2);
3. diffusion to, and reactions in, erythrocytes of the
circulating blood (Reactions 3–5).
In addition, NO is effectively scavenged by the inflam-
matory superoxide radical anion ·O2
− [3].
High incidence and flatness of neoplasms
at the air-interface
The rate of diffusion of NO to ambient air lowers the iNOS-
produced excess of NO in neoplasms of the skin. Its transport to
the 12–20 times per minute inhaled/exhaled air of the lungs
also suppresses its concentration in neoplasms of the lung.
Possibly because neoplasms at air interfaces lose their excess
NO concentration, they survive the immune system’s NO
attack making the development of cancers of the skin and the
lung more likely than the development of other cancers. Of the
2.1 million new (2008) cancers in the USA, more than
1,062,000 are projected to be cancers of the skin and 215,000
of the lung [4]. While the mutagenic-carcinogenic effect of
UV-B exposure of the skin and the effects of airborne
carcinogens on the lung are not questioned, the high incidence
of air-contacting cancers suggests that loss of tumor NO to air
should also be considered among the causes of the high
incidence of skin and lung cancers.
The suggestion that NO transport from a neoplasm to air
blunts the NO attack of the immune system is supported by the
shapes and loci of the early skin and lung cancers. If out-
diffusion of NO to ambient air would not be of essence, i.e. if
the likelihood of apoptosis of cells would not increase with their
distance from the air-interface, then the proliferation of cancer-
cells would be isotropic and tumors would grow to be about
spherical. If, however, those cells that are nearer to air-interface
would survive the NO attack, while those removed from the air-
interface would undergo apoptosis, then the nascent neoplasms
would be flat, nearly two-dimensional. Their estimated
thickness would be a small multiple of the NO diffusion
length, estimated at 0.1–1 mm for tissues other than blood, i.e.
for not-yet-vascularized neoplasms. Indeed, most of the nascent
cancers of the skin are at the air-interface: skin cancers begin at
the dermal–epidermal junction, and invade only later the deeper
fatty dermis. Skin cancers starting at the dermal–epidermal
junction include basal cell carcinomas, squamous cell carcino-
mas, and melanomas. Many of the early lung cancers are also
confined to the lining at the air-interface. Small cell lung
carcinomas arise mostly in the mucosal layer of one of the large
bronchi, over which the air-flow is particularly rapid. Many
lung cancers start in cells at the mucosa of a bronchus, the cells
undergoing squamous metaplasia, i.e. morphing into squamous
cells. For this reason, oncological pathologists examining lung
cancers always look for evidence of in situ carcinoma in the
bronchial mucosa. Fast air-flow makes the boundary layer thin
(boundary layer is the engineering term for the interfacial layer
across which the NO concentration drops). As a consequence
of the thin boundary layer, the rate of the out-diffusion of NO,
which scales with the NO concentration gradient, is rapid. In
peripheral, non-bronchial lung adenocarcinomas the growth
also starts in the mucosal lining at the air-interface.
Body fat and cancer
In the absence of an NO-oxidation catalyst, the rate of the
ter-molecular reaction whereby NO is oxidized by O2 to
NO2 (Reaction 2) scales with the square of the NO
concentration and with the cube of the dissolved gas
concentration. The solubilities of NO and O2 in lipids
exceed about threefold their solubilities in pH 7.4 aqueous
saline solutions [5]. This greater lipid solubility of NO
2 NOþ O2 ! 2 NO2 ð2Þ
should lead to its extraction from a neoplasm by proximal
adipose tissue. Because of the threefold higher NO and O2
concentrations in fat, the rate of the NO-eliminating
Reaction 2 is at least tenfold faster than it is in a non-
fatty tissue. As the breast is constituted mostly of fatty
tissue, breast carcinomas are often proximal to, or within,
fat. That obesity and cancer are positively correlated is
documented in more than 530 publications, about 140 on
cancers of the breast.
Angiogenesis and the virulence of cancers
Neoplasms turn into aggressive cancers when they are
vascularized. The rate of loss of NO to circulating blood
dwarfs the rates of its loss to air or to fat. Reactions 3–5
dominate the elimination of NO by blood. These reactions
are fast and drastically limit the blood NO concentration
[6]. Cancers in which Reactions 3–5 may affect the cellular
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NO concentrations already at the nascent stage include
leukemia and lymphomas. NO elimination by blood is,
however, most important in mature, vascularized tumors.
The lifetime work of the late Judah Folkman and of his
associates established through the past 40 years the relative
dormancy of cancers until their vascularization. They
showed that angiogenesis, leading to vascularization, makes
the tumors virulent [7, 8].
The erythrocyte volume fraction (hematocrit) in blood is
near 0.45. Because oxyhemoglobin (HbFe(II)O2) consti-
tutes 35% of the wet-weight of the erythrocytes, blood
contains 16 wt% HbFe(II)O2. The molecular mass of HbFe
(II)O2 is 64,000 and each molecule comprises two β-
chains, each with a cys93. Thus, the concentration of the
NO-reactive cys93 in blood is as high as 5 mM. The NO
concentration gradient near a tumor blood vessel is so large
that it can be said that the circulating blood sucks out the
excess NO of the immune system’s attack. Now the rate of
cell proliferation is no longer diminished by high NO-
concentration-triggered apoptosis.
HbFe IIð ÞO2cys93 SHþ NO
$ HbFe IIð ÞO2cys93 SNOþ Hþ þ e ð3Þ
Glutathione SHþ NO$ Glutathione  SNOþ Hþ þ e
ð4Þ
HbFe IIð ÞO2 þ NO! metHbFe IIIð Þ þ NO3 ð5Þ
Implantable NO-monitoring electrodes
Although implantable electrodes with a wide dynamic
range, suitable for monitoring NO in living tumors, are not
yet in hand, there are electrodes that could be modified for
this purpose. Tadeusz Malinski pioneered tissue-implanted
amperometric NO sensors, based on porphyrin-catalyzed
electrooxidation of NO [9–11]. He designed, for example,
1–20 μm diameter sensors, detecting 10−9M NO, with a 0.1–
10 ms response time, protected by an i.v. catheter or a Swan-
Ganz catheter. He applied such sensors in the monitoring of
NO in the cardiovascular system [12, 13]. Subsequent NO-
monitoring electrodes were implanted in organs of animals,
particularly in rats, including their retina and brain [14–16].
The porphyrinic and phthalocyanine-based catalysts were
improved through derivatization and screening of large
libraries [17, 18] and nickel-containing porphyrinic and
phthalocyanine-based electrocatalysts are now preferred for
in vivo applications [19–24]. Indeed, the latter have already
been implanted in a tumor [25]. Membranes improved the
specificity of the electrodes in vivo. [26, 27]. High spatial
resolution was achieved [28] and the electrodes’ diameter
has been reduced to nanometers with the NO detection limit
lowered to 0.3 nM. [29, 30]. Platinized platinum [31] and
platinum–iridium anodes have also been introduced [32] and
microchip-based, membrane-coated NO microsensors
have been described [23]. Of the recently reported
electrochemical-amperometric NO sensors, those of Shin et
al. and Thangavel et al. might develop into particularly
useful tumor NO-monitoring systems [33, 34]. A current
review summarizes the principles and status of NO-
monitoring electrodes [35].
Conclusion
The considerations presented suggest that cancer research
and oncological practice would benefit from in-tumor
monitoring of the actual concentration of NO. An increase
in the NO concentration in a tumor to >1 μM would
indicate effective treatment and would be a favorable
prognostic indicator.
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